Advice
Following a full submission
entecavir (Baraclude) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase levels and histological evidence of active inflammation and or fibrosis.
Clinical studies have shown that entecavir is more effective than lamivudine in nucleosidenaïve HBeAg positive and negative patients and in lamivudine refractory patients.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- entecavir, 0.5 and 1mg tablets (Baraclude)
- SMC ID:
- 320/06
- Indication:
- Hepatitis B
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 October 2006